Canopy Biosciences and Enable Medicine Announce Partnership to Bring Advanced Spatial Analysis Pipelines to the ChipCytometry Platform
Canopy Biosciences and Enable Medicine have partnered to enhance the Canopy CellScape system for spatial biology through advanced analysis and cloud-based analytics. This collaboration integrates Enable's analysis tools, including cluster and neighborhood analysis, into the CellScape system, which allows for the detection of multiple protein targets and facilitates high-plex spatial proteomics.
The partnership aims to streamline data analysis for research applications, promising to enhance quantitative insights and discovery capabilities in spatial biology. This integrated data workflow will be showcased at the upcoming AACR annual meeting in April 2023.
- Partnership enhances the Canopy CellScape system with advanced spatial analysis tools.
- Integration with Enable's cloud platform improves data analytics for research applications.
- None.
Enable Cloud Platform to be Available with Canopy CellScape System for High-Plex Spatial Biology
Canopy Biosciences’
The Canopy CellScape system allows for quantitative, high-plex spatial proteomics imaging with leading quantitative performance. Enable Medicine’s Enable Cloud platform accelerates biological insights via advanced spatial analytics and cloud-based workflows for spatial biology. Integrating the Enable Cloud Platform into the
“The CellScape system delivers best-in-class quantitative spatial proteomics data through our proprietary, 8-log high-dynamic range (HDR) imaging.” said
“Enable Medicine is committed to accelerating biological insights by analyzing large and complex spatial biology datasets on the cloud,” added
Canopy Biosciences and Enable Medicine will showcase their integrated data workflow at the
About
Combining an advanced, purpose-built imaging system with easy-to-use fluidics for walk-away automation, the
About Canopy Biosciences, a
Canopy Biosciences was formed in 2016 and rapidly built a comprehensive portfolio of products and services for spatial biology, multi-omics, and bioprocessing. Canopy offers its ChipCytometry™ technology for precise spatial multiplexing in cells and tissue samples, along with other technologies for single-cell RNAseq, bulk RNAseq, and other gene expression analysis services. Canopy Biosciences is headquartered in
About
Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular and cell biology research, in applied and pharma applications, in microscopy and nanoanalysis, as well as in industrial applications. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit: www.bruker.com.
About Enable Medicine
At Enable Medicine, our mission is to improve the outcomes for patients suffering from serious disease by building tools that maximize the effectiveness of drug or cell therapies. To this end, we have developed an end-to-end solution for interpreting spatial biology that is used by hundreds of scientists. The Enable platform allows generation of multi-modal data from patient samples and extraction of translational insights. The platform empowers users to comprehensively search and re-interpret a growing knowledge bank composed of petabytes of spatial-omics data from billions of measurements taken across 500M+ single cells from 20,000+ patients with clinical data. Our complete images to insights service is based on our cloud-based technology to escalate discovery of novel insights from research data. De-risk your clinical development through mechanism of action determination, biomarker identification, and patient stratification. At Enable Medicine, we are dedicated to improving patient outcomes through our cutting-edge technology and innovative solutions. Learn more about Enable Medicine at https://www.enablemedicine.com/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230412005195/en/
Investor:
Senior Director, Investor Relations & Corporate Development
T: +1 (978) 663-3660 x1479
E: Investor.Relations@bruker.com
Media:
Vice President, Marketing and R&D
Canopy Biosciences, A
T: +1 (314) 662-9987
E: kevin.gamber@bruker.com
Source:
FAQ
What is the recent partnership involving Canopy Biosciences and Enable Medicine?
How does the partnership between Canopy Biosciences and Enable Medicine benefit spatial biology?
When will the new features from the partnership be showcased?
What is the significance of the Canopy CellScape system?